MIRA Pharmaceuticals submits Ketamir-2 Phase 2a protocol for IRB review

September 17, 2026 8:30 AM

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced that its Phase 2a clinical protocol for Ketamir-2, an oral NMDA receptor modulator, has ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found